Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial

OBJECTIVE: This post hoc analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent response to subcutaneous (SC) abatacept in patients with psoriatic arthritis (PsA). METHODS: In ASTRAEA, patients with active...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: McInnes, Iain B, Ferraccioli, Gianfranco, D'Agostino, Maria-Antonietta, Le Bars, Manuela, Banerjee, Subhashis, Ahmad, Harris A, Elbez, Yedid, Mease, Philip J
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Psoriatic Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6560664/
https://ncbi.nlm.nih.gov/pubmed/31245054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2019-000934
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados